212 related articles for article (PubMed ID: 19402060)
21. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
Figlin RA; Abi-Aad AS; Belldegrun A; deKernion JB
Semin Oncol; 1991 Oct; 18(5 Suppl 7):102-7. PubMed ID: 1719641
[TBL] [Abstract][Full Text] [Related]
22. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
23. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
24. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
Bukowski RM
Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma.
Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC
Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy in renal cell carcinoma.
Bukowski RM
Oncology (Williston Park); 1999 Jun; 13(6):801-10; discussion 810, 813. PubMed ID: 10378218
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Kudo-Saito C; Wansley EK; Gruys ME; Wiltrout R; Schlom J; Hodge JW
Clin Cancer Res; 2007 Mar; 13(6):1936-46. PubMed ID: 17363550
[TBL] [Abstract][Full Text] [Related]
28. [Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient].
Heinzer H; Huland E; Huland H
Urologe A; 2003 Nov; 42(11):1450-2. PubMed ID: 14624342
[TBL] [Abstract][Full Text] [Related]
29. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
Atkins MB; Regan M; McDermott D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of metastatic renal cell cancer.
Fishman M; Seigne J
Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
McDermott DF; Regan MM; Atkins MB
Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
[TBL] [Abstract][Full Text] [Related]
33. Metastatic renal cell cancer treatments.
Sternberg CN
Drugs Today (Barc); 2003; 39 Suppl C():39-59. PubMed ID: 14988745
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-2 and interferon in renal cell carcinoma.
Wersäll P
Med Oncol Tumor Pharmacother; 1993; 10(1-2):71-6. PubMed ID: 7505042
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy and targeted therapy combinations in renal cancer.
McDermott DF
Curr Clin Pharmacol; 2011 Aug; 6(3):207-13. PubMed ID: 21827391
[TBL] [Abstract][Full Text] [Related]
37. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
[TBL] [Abstract][Full Text] [Related]
38. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
Négrier S; Philip T
Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
[TBL] [Abstract][Full Text] [Related]
39. Unusual gastric and pancreatic metastatic renal cell carcinoma presentation 10 years after surgery and immunotherapy: A case report and a review of literature.
Riviello C; Tanini I; Cipriani G; Pantaleo P; Nozzoli C; Poma A; Riccardo V; Valeri A
World J Gastroenterol; 2006 Aug; 12(32):5234-6. PubMed ID: 16937540
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
